Research ArticleArticle
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial
Michael E. Weinblatt, Arthur Kavanaugh, Mark C. Genovese, David A. Jones, Theresa K. Musser, Elliott B. Grossbard and Daniel B. Magilavy
The Journal of Rheumatology February 2013, jrheum.120923; DOI: https://doi.org/10.3899/jrheum.120923
Michael E. Weinblatt
From the Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts; University of California, San Diego, California; Stanford University, Palo Alto, California; AstraZeneca, Macclesfield, UK; and Rigel Pharmaceuticals Inc., South San Francisco, California, USA. Supported by Rigel Pharmaceuticals Inc. Dr. Weinblatt serves as a consultant to Rigel and AstraZeneca. Dr. Genovese serves as a consultant to Rigel and AstraZeneca and receives grant/research support from Rigel and AstraZeneca. Mr. Jones is an employee of AstraZeneca. Ms. Musser, Dr. Grossbard, and Dr. Magilavy are employees of Rigel. M.E. Weinblatt, MD, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School; A. Kavanaugh, MD, University of California; M.C. Genovese, MD, Stanford University; D.A. Jones, MSc, AstraZeneca; T.K. Musser, BA; E.B. Grossbard, MD; D.B. Magilavy, MD, Rigel Pharmaceuticals Inc. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: MWEINBLATT@PARTNERS.ORG Accepted for publication December 4, 2012.
Arthur Kavanaugh
From the Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts; University of California, San Diego, California; Stanford University, Palo Alto, California; AstraZeneca, Macclesfield, UK; and Rigel Pharmaceuticals Inc., South San Francisco, California, USA. Supported by Rigel Pharmaceuticals Inc. Dr. Weinblatt serves as a consultant to Rigel and AstraZeneca. Dr. Genovese serves as a consultant to Rigel and AstraZeneca and receives grant/research support from Rigel and AstraZeneca. Mr. Jones is an employee of AstraZeneca. Ms. Musser, Dr. Grossbard, and Dr. Magilavy are employees of Rigel. M.E. Weinblatt, MD, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School; A. Kavanaugh, MD, University of California; M.C. Genovese, MD, Stanford University; D.A. Jones, MSc, AstraZeneca; T.K. Musser, BA; E.B. Grossbard, MD; D.B. Magilavy, MD, Rigel Pharmaceuticals Inc. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: MWEINBLATT@PARTNERS.ORG Accepted for publication December 4, 2012.
Mark C. Genovese
From the Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts; University of California, San Diego, California; Stanford University, Palo Alto, California; AstraZeneca, Macclesfield, UK; and Rigel Pharmaceuticals Inc., South San Francisco, California, USA. Supported by Rigel Pharmaceuticals Inc. Dr. Weinblatt serves as a consultant to Rigel and AstraZeneca. Dr. Genovese serves as a consultant to Rigel and AstraZeneca and receives grant/research support from Rigel and AstraZeneca. Mr. Jones is an employee of AstraZeneca. Ms. Musser, Dr. Grossbard, and Dr. Magilavy are employees of Rigel. M.E. Weinblatt, MD, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School; A. Kavanaugh, MD, University of California; M.C. Genovese, MD, Stanford University; D.A. Jones, MSc, AstraZeneca; T.K. Musser, BA; E.B. Grossbard, MD; D.B. Magilavy, MD, Rigel Pharmaceuticals Inc. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: MWEINBLATT@PARTNERS.ORG Accepted for publication December 4, 2012.
David A. Jones
From the Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts; University of California, San Diego, California; Stanford University, Palo Alto, California; AstraZeneca, Macclesfield, UK; and Rigel Pharmaceuticals Inc., South San Francisco, California, USA. Supported by Rigel Pharmaceuticals Inc. Dr. Weinblatt serves as a consultant to Rigel and AstraZeneca. Dr. Genovese serves as a consultant to Rigel and AstraZeneca and receives grant/research support from Rigel and AstraZeneca. Mr. Jones is an employee of AstraZeneca. Ms. Musser, Dr. Grossbard, and Dr. Magilavy are employees of Rigel. M.E. Weinblatt, MD, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School; A. Kavanaugh, MD, University of California; M.C. Genovese, MD, Stanford University; D.A. Jones, MSc, AstraZeneca; T.K. Musser, BA; E.B. Grossbard, MD; D.B. Magilavy, MD, Rigel Pharmaceuticals Inc. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: MWEINBLATT@PARTNERS.ORG Accepted for publication December 4, 2012.
Theresa K. Musser
From the Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts; University of California, San Diego, California; Stanford University, Palo Alto, California; AstraZeneca, Macclesfield, UK; and Rigel Pharmaceuticals Inc., South San Francisco, California, USA. Supported by Rigel Pharmaceuticals Inc. Dr. Weinblatt serves as a consultant to Rigel and AstraZeneca. Dr. Genovese serves as a consultant to Rigel and AstraZeneca and receives grant/research support from Rigel and AstraZeneca. Mr. Jones is an employee of AstraZeneca. Ms. Musser, Dr. Grossbard, and Dr. Magilavy are employees of Rigel. M.E. Weinblatt, MD, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School; A. Kavanaugh, MD, University of California; M.C. Genovese, MD, Stanford University; D.A. Jones, MSc, AstraZeneca; T.K. Musser, BA; E.B. Grossbard, MD; D.B. Magilavy, MD, Rigel Pharmaceuticals Inc. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: MWEINBLATT@PARTNERS.ORG Accepted for publication December 4, 2012.
Elliott B. Grossbard
From the Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts; University of California, San Diego, California; Stanford University, Palo Alto, California; AstraZeneca, Macclesfield, UK; and Rigel Pharmaceuticals Inc., South San Francisco, California, USA. Supported by Rigel Pharmaceuticals Inc. Dr. Weinblatt serves as a consultant to Rigel and AstraZeneca. Dr. Genovese serves as a consultant to Rigel and AstraZeneca and receives grant/research support from Rigel and AstraZeneca. Mr. Jones is an employee of AstraZeneca. Ms. Musser, Dr. Grossbard, and Dr. Magilavy are employees of Rigel. M.E. Weinblatt, MD, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School; A. Kavanaugh, MD, University of California; M.C. Genovese, MD, Stanford University; D.A. Jones, MSc, AstraZeneca; T.K. Musser, BA; E.B. Grossbard, MD; D.B. Magilavy, MD, Rigel Pharmaceuticals Inc. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: MWEINBLATT@PARTNERS.ORG Accepted for publication December 4, 2012.
Daniel B. Magilavy
From the Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts; University of California, San Diego, California; Stanford University, Palo Alto, California; AstraZeneca, Macclesfield, UK; and Rigel Pharmaceuticals Inc., South San Francisco, California, USA. Supported by Rigel Pharmaceuticals Inc. Dr. Weinblatt serves as a consultant to Rigel and AstraZeneca. Dr. Genovese serves as a consultant to Rigel and AstraZeneca and receives grant/research support from Rigel and AstraZeneca. Mr. Jones is an employee of AstraZeneca. Ms. Musser, Dr. Grossbard, and Dr. Magilavy are employees of Rigel. M.E. Weinblatt, MD, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, and Harvard Medical School; A. Kavanaugh, MD, University of California; M.C. Genovese, MD, Stanford University; D.A. Jones, MSc, AstraZeneca; T.K. Musser, BA; E.B. Grossbard, MD; D.B. Magilavy, MD, Rigel Pharmaceuticals Inc. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: MWEINBLATT@PARTNERS.ORG Accepted for publication December 4, 2012.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial
Michael E. Weinblatt, Arthur Kavanaugh, Mark C. Genovese, David A. Jones, Theresa K. Musser, Elliott B. Grossbard, Daniel B. Magilavy
The Journal of Rheumatology Feb 2013, jrheum.120923; DOI: 10.3899/jrheum.120923
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial
Michael E. Weinblatt, Arthur Kavanaugh, Mark C. Genovese, David A. Jones, Theresa K. Musser, Elliott B. Grossbard, Daniel B. Magilavy
The Journal of Rheumatology Feb 2013, jrheum.120923; DOI: 10.3899/jrheum.120923